Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer

International Journal of Cancer

Volumn 135, Issue 6, 2014, Pages 1390-1398

  Mimura, Kousaku ^a   Kamiya, Takahiro ^a   Shiraishi, Kensuke ^a,b   Kua, Ley Fang ^a   Shabbir, Asim ^a   So, Jimmy ^a   Yong, Wei Peng ^a   Suzuki, Yoshiyuki ^c   Yoshimoto, Yuya ^c   Nakano, Takashi ^c   Fujii, Hideki ^b   Campana, Dario ^a   Kono, Koji ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

ADCC; gastric cancer; MICs; NK cells; NKG2D; ULBPs

Indexed keywords

INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL EXPANSION; CELL THERAPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; THERAPY EFFECT; TREATMENT RESPONSE;

ADCC; GASTRIC CANCER; MICS; NK CELLS; NKG2D; ULBPS;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, SCID; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84904052770     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28780     Document Type: Article

References (28)

1. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
2. Lee J, Lim Do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-73.
3. Kono K, Takahashi A, Ichihara F, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 2002; 8: 1767-71.
4. Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006; 26: 2237-42.
5. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-19.
6. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
7. Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-9.
8. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-9.
9. Moretta L, Locatelli F, Pende D, et al. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011; 117: 764-71.
10. Bae DS, Hwang YK, Lee JK,. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. Cell Immunol 2012; 276: 122-7.
11. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69: 4010-17.
12. Imai C, Iwamoto S, Campana D,. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106: 376-83.
13. Ando T, Mimura K, Johansson CC, et al. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J Immunol 2008; 181: 8382-90.
14. Bae J, Carrasco R, Lee AH, et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia 2011; 25: 1610-19.
15. Okita R, Mougiakakos D, Ando T, et al. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol 2012; 188: 2136-45.
16. Lu X, Ohata K, Kondo Y, et al. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 2010; 101: 609-15.
17. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-9.
18. Kono K, Takahashi A, Ichihara F, et al. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 2002; 62: 5813-17.
19. Mimura K, Kono K, Maruyama T, et al. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. Int J Cancer 2011; 129: 2408-16.
20. Shiraishi K, Mimura K, Izawa S, et al. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer 2013; 16: 571-80.
21. Voskens CJ, Watanabe R, Rollins S, et al. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res 2010; 29: 134-42.
22. Cho D, Shook DR, Shimasaki N, et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010; 16: 3901-9.
23. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
24. Izawa S, Kono K, Mimura K, Kawaguchi Y, Watanabe M, Maruyama T, Fujii H,. H(2)O(2) production within tumor microenvironment inversely correlated with infiltration of CD56(dim) NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. Cancer Immunol Immunother 2011; 60: 1801-10.
25. Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879-84.
26. Eager R, Harle L, Nemunaitis JJ,. Lung cancer vaccines. Curr Gene Ther 2007; 7: 469-84.
27. McGilvray RW, Eagle RA, Watson NF, et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009; 15: 6993-7002.
28. Morgado S, Sanchez-Correa B, Casado JG, et al. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun 2011; 3: 365-73.